Recently, the combination of the immune checkpoint inhibitors (ICIs) atezolizumab plus theanti-vascular endothelial growth factor (VEGF) antibody bevacizumab as the first-line treatment of advanced HCC showed better overall survival (OS) compared with sorafenib, and this systemic combination therapy has been recommended as the first-line therapy for HCC patients with PVTT (9). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.